Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz Jared Holz, Mizuho, ...

Here are some of the major companies whose stocks moved on the week’s news.

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...

Health-care companies rose as traders rotated back into the sector amid optimism about blockbuster drugs. Novo Nordisk shares rose by more than 8% for one of their biggest gains in recent years after ...

The Kokomo woman was prediabetic when she asked her doctor about Ozempic, the popular anti-diabetic drug. Usually prescribed ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.

A successful retirement plan takes advantage of favorable market conditions while safeguarding against downturns. Here's what ...

Amgen executives and employees, local and state elected dignitaries, and an assortment of other local economic development ...

$ 78.9079 0.2179 0.28% ...